p applicant Genentech Inc 
XTalks
APRIL 26, 2023
He began his career in business development and commercial strategy roles at Genentech. Hear more about the innovative technology and application of DermaSensor in this episode. Carli P, Nardini P, Crocetti E, De Giorgi V, Giannotti B. Data on File, DermaSensor Inc. Melanoma Res 2004;14(5):403-407.
Pfizer
FEBRUARY 9, 2023
BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. 0b013e3182a3516e 9 Piot P, Larson HJ, O'Brien KL, et al. For more information, please visit www.BioNTech.com.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 1, 2020
Rowe Price Associates, Inc., Most recently, Genesis announced a multi-target partnership with Genentech. .–( BUSINESS WIRE )– Genesis Therapeutics , a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, has completed its $52M Series A financing round.
The Pharma Data
NOVEMBER 20, 2020
and plan to submit applications immediately to other regulatory agencies around the world. NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Friday, November 20, 2020 — Pfizer Inc. . NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Friday, November 20, 2020 — Pfizer Inc.
The Pharma Data
JUNE 18, 2021
It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. 1.35]; P=0.49). It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. Avoid concomitant use of P-gp and BCRP inhibitors at initiation and during the dose titration phase. AbbVie Inc.
The Pharma Data
DECEMBER 1, 2020
NEW YORK & MAINZ, Germany–( BUSINESS WIRE )– Pfizer Inc. Food and Drug Administration (FDA) and have submitted the final Conditional Marketing Authorization Application (CA) following rolling submissions with the European Medicines Agency (EMA) and several other regulatory agencies around the world. 2, 2020 07:05 UTC.
The Pharma Data
JUNE 18, 2021
The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. vs. 11.4%) (p < 0.0001).
Expert insights. Personalized for you.
52 
Let's personalize your content